If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

Share Price is delayed by 15 minutes
Get Live Data
146.50    0.50 (0.34%)
Bid:
145.00
Ask:
148.00
Spread: 3.00 (2.069%)
Market Cap: £123.98m
DXRX Live PriceLast checked at - London Stock Exchange

Intraday Diaceutics Share Chart

Directorate Change

22 Dec 2020 07:01

RNS Number : 4363J
Diaceutics PLC
22 December 2020
 

 

Diaceutics PLC

("Diaceutics" or the "Company")

 

Directorate change

 

Diaceutics PLC (AIM: DXRX), announces the appointment of Deborah Davis as Non-Executive Chair, effective from 4 January 2021. Deborah has extensive global experience in platform business models, software, fintech, telecoms and e-commerce businesses.

 

After completing her undergraduate studies in Australia, Deborah spent 25 years in CEO and executive roles including 14 years in European and global senior leadership roles at internet platform businesses PayPal and eBay, and technology companies Symantec and Verizon. 

 

She currently holds a number of Non-Executive Director and Board committee positions, including International Personal Finance plc, IDEX Biometrics ASA, Norway, The Institute of Directors UK and Which? Ltd (until 31/12/20). Her previous Board experience also includes private equity based ieDigital. Deborah is a trustee of the Southern African Conservation Trust.

 

Deborah is a Chartered Director and a Fellow of the Institute of Directors. She holds a Bachelor of Applied Science (Electronics) Honours degree from the University of Melbourne and a Sloan Masters in Science (Management) with Distinction from London Business School.

 

Peter Keeling, Chief Executive Officer of Diaceutics said: "I am delighted to attract someone of Deborah's relevant technology background and global experience to join our mission at Diaceutics. With the recent pivotal launch of our DXRX - Precision Testing Network platform, we have truly entered a new chapter in the Company's trajectory and I look forward to working with Deborah to capitalise on this."

 

Information required to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

 

Deborah Lee Davis (Llewelyn), aged 57, is currently or has previously been a director or partner of the following directorships or partnerships within the past five years:

 

Current directorships/partnerships

Historic directorships/partnerships

IPF PLC

IE DIGITAL (formerly Intelligent Environments Europe)

Institute of Directors

IDEX Biometrics ASA

WHICH? LTD

SA CONSERVATION TRUST

 

Save for the information disclosed above, there is no other information to be disclosed on Deborah Davis under Schedule 2(g) of the AIM Rules.

 

Deborah holds no shares in the Company.

 

Enquiries:

 

Diaceutics PLC

www.diaceutics.com

Peter Keeling, Chief Executive Officer

via Walbrook PR

Philip White, Chief Financial Officer

Cenkos Securities plc (Nominated adviser and broker)

+44 (0) 20 7391 8900

Callum Davidson / Giles Balleny

Michael Johnson (Sales)

Walbrook PR

Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com

Anna Dunphy

Mob: +44 (0)7876 741 001

Paul McManus

Mob: +44 (0)7980 541 893

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - a proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries. www.diaceutics.com

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAKKDBNOBDDCBB
Date   Source Headline
1st Sep 20217:00 amRNSPDMR Shareholding/Share Incentive Plan
31st Aug 20217:00 amRNSNotice of Investor Presentation
30th Jul 20214:54 pmRNSPDMR Shareholding/Share Incentive Plan
8th Jul 20217:00 amRNSTrading Update
1st Jul 20217:00 amRNSIssue of Share Options and PDMR Shareholdings
29th Jun 20214:56 pmRNSPDMR Shareholding/Share Incentive Plan
24th Jun 20217:00 amRNSNew Contract Wins
18th Jun 20217:00 amRNSPurchase of Shares and PDMR Shareholding
16th Jun 20217:00 amRNSCapital Markets Day and KPI Update
7th Jun 20216:23 pmRNSPDMR Shareholding/Share Incentive Plan
7th Jun 20217:00 amRNSNotice of Capital Markets Day
4th Jun 20217:00 amRNSPresenting data on COVID impact on cancer at ASCO
21st May 20211:49 pmRNSHolding(s) in Company
21st May 20217:00 amRNSChange of Adviser
19th May 20213:24 pmRNSResult of AGM
13th May 20217:00 amRNSLGC SeraCare Partnership
12th May 20215:58 pmRNSSale of Shares and PDMR Shareholding
5th May 20216:03 pmRNSHolding(s) in Company
4th May 20213:11 pmRNSSale of Shares and Director/PDMR Shareholding
30th Apr 202111:01 amRNSShare Incentive Plan
21st Apr 20217:00 amRNSNotice of AGM and posting of Annual Report
12th Apr 20217:00 amRNSNew Vice President of Operations in Asia
8th Apr 20219:49 amRNSTransfer of Shares and Director/PDMR Shareholding
7th Apr 20217:58 amRNSTransfer of Shares and Director/PDMR Shareholding
6th Apr 202111:12 amRNSIssue of Share Options/PDMR Shareholdings
1st Apr 20217:00 amRNSCOVID-19 Testing Data licensing agreement
30th Mar 20217:00 amRNSNew lease agreement and related party transaction
15th Mar 20217:00 amRNSFinal Results
8th Mar 20217:00 amRNSNotice of Results
4th Mar 202112:49 pmRNSNew Vice President of Finance appointment
21st Jan 20217:00 amRNSQuarterly media update
11th Jan 20219:56 amRNSHolding(s) in Company
11th Jan 20217:00 amRNSTrading update
22nd Dec 20207:01 amRNSDirectorate Change
22nd Dec 20207:00 amRNSDirectorate Change
10th Dec 20203:10 pmRNSHolding(s) in Company
17th Nov 20207:00 amRNSEuropean international award win
10th Nov 20204:32 pmRNSHolding(s) in Company
28th Oct 20207:00 amRNSCommercial launch of DXRX
7th Sep 20202:05 pmRNSSecond Price Monitoring Extn
7th Sep 20202:00 pmRNSPrice Monitoring Extension
7th Sep 202011:00 amRNSPrice Monitoring Extension
7th Sep 20207:00 amRNSHalf-year Report
27th Aug 20207:00 amRNSNotice of Results
22nd Jul 20207:00 amRNSNew contract win for DXRX platform
9th Jul 20207:00 amRNSHolding(s) in Company
8th Jul 20207:00 amRNSTrading update
6th Jul 20204:41 pmRNSSecond Price Monitoring Extn
6th Jul 20204:36 pmRNSPrice Monitoring Extension
3rd Jul 202010:43 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.